摘要

【摘要】
目的 比较首发性精神分裂症患者应用利培酮与氨磺必利两种药物的治疗效果及安全性方面的影响。

方法 选取我院2020年1月2022年10月期间92例精神分裂症患者，根据治疗方式不同分组。利培酮组46例给予利培酮治疗，氨磺必利组46例给予氨磺必利药物治疗，治疗六周后对比临床疗效，精神症状严重程度：阳性与阴性综合征量表（Positive and Negative Syndrome Scale,PANSS）各项评分；生活质量：生活质量（Generic Quality of Life Inventory，GQOLI-74）评分及不良反应。

结果 两组患者PANSS评分和有效率无统计学意义（P>0.05）；治疗后氨磺必利组GQOLI-74各项评分均高于利培酮组，不良反应发生率低于利培酮组，有统计学意义（P<0.05）。

结论 对于首发性精神分裂症患者，使用氨磺必利、利培酮药物均可改善精神临床症状且治疗效果相当，但氨磺必利对生活质量影响较小，安全性高于利培酮。

关键词：【关键词】利培酮；氨磺必利；首发性；精神分裂症

ABSTRACT

[Abstract]
Objective To explore the therapeutic effect of risperidone and amisulpride in patients with first-episode schizophrenia, as well as the influence on mental symptoms and safety.

Methods Ninety-two patients with schizophrenia from January 2020 to October 2022 in our hospital were selected and grouped according to different treatment methods. Forty-six patients in the risperidone group were treated with risperidone, and 46 patients in the amsulpride group were treated with amsulpride. After six weeks of treatment, the clinical efficacy was compared including: Positive and Negative Syndrome Scale (PANSS) scores; Quality of Life: Generic Quality of Life Inventory (GQOLI-74) score and adverse reactions.

Results There was no statistical significance in PANSS score and effective rate between 2 groups (P>0.05). After treatment, the scores of GQOLI-74 in amisulapride group were higher than those in risperidone group, and the incidence of adverse reactions was lower than that in risperidone group (P<0.05).

Conclusion   For patients with first-episode schizophrenia, the use of amisulpride and risperidone can improve the psychiatric clinical symptoms and the therapeutic effect is similar, but amisulpride has little effect on the quality of life and is safer than risperidone.

Key words: [Key words] Risperidone; Amisulpride; Primacy; schizophrenia